Ginkgo Bioworks Holdings, Inc. (DNA)

Ginkgo Bioworks Holdings, Inc. (DNA) is a healthcare company (biotechnology) based in the United States. The share price is $8.40, down 1.24% on the day, which values the company at $544.21M. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$8.40−1.24% today
Market value
$544.21M
Funk Score
37/100
Against its own history
Well below its usual priceusual price $16.61
200-week average
$27.1569% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Ginkgo Bioworks Holdings, Inc. in more detail

DNA trades at -2.9× next year's expected earnings, 4.2× sales. Measured against its own history, the price is 49% below what its usual multiples would imply ($16.61) — well below its usual price. It sits 69% below its 200-week average of $27.15.

Over the last five fiscal years Ginkgo Bioworks Holdings, Inc. has compounded revenue 17.3% a year. Its Funk Score is 37 out of 100 (financial strength 3.4, profitability 2.0, growth 4.3, value 5.0, each out of 10).

In its favour: Operating margin is expanding. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

1 of the superinvestors tracked here hold DNA, including Andreas Halvorsen (0.1% of the portfolio).

Superinvestors holding DNA

1 of the investors tracked here report a position in their latest 13F filing.

Ginkgo Bioworks Holdings, Inc. (DNA): questions and answers

What is Ginkgo Bioworks Holdings, Inc.'s market cap?

Ginkgo Bioworks Holdings, Inc. is valued at $544.21M at a share price of $8.40.

Is DNA overvalued or undervalued?

Against its own history, DNA is well below its usual price: the price is 49% below the $16.61 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is DNA above its 200-week moving average?

No. DNA is 69.1% below its 200-week average of $27.15. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Ginkgo Bioworks Holdings, Inc. growing?

Over the last five fiscal years Ginkgo Bioworks Holdings, Inc.'s revenue grew 17.3% a year.

Does DNA pay a dividend?

Ginkgo Bioworks Holdings, Inc. does not currently pay a regular dividend.

Which famous investors own DNA?

In their latest quarterly filings, Andreas Halvorsen (0.1% of the portfolio) hold DNA. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Ginkgo Bioworks Holdings, Inc. (DNA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/DNA

Underlying data: Yahoo Finance; company filings with the SEC.